Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
 
Users online: 2718  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page


 
Table of Contents 
CORRESPONDENCE
Year : 2011  |  Volume : 56  |  Issue : 1  |  Page : 122-123
Practical issues for clinicians using high-dose intravenous immunoglobulin


1 Department of Immunology, Frimley Park Hospital NHS Foundation Trust, Frimley, Camberley, Surrey, GU16 7UJ, United Kingdom
2 Department of Paediatrics, Advanced Paediatric Centre, Post Graduate Institute of Medical Education and Research, Chandigarh-160012, India

Date of Web Publication10-Mar-2011

Correspondence Address:
S Khan
Department of Immunology, Frimley Park Hospital NHS Foundation Trust, Frimley, Camberley, Surrey, GU16 7UJ
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5154.77580

Rights and Permissions



How to cite this article:
Khan S, Singh S. Practical issues for clinicians using high-dose intravenous immunoglobulin. Indian J Dermatol 2011;56:122-3

How to cite this URL:
Khan S, Singh S. Practical issues for clinicians using high-dose intravenous immunoglobulin. Indian J Dermatol [serial online] 2011 [cited 2019 Jul 18];56:122-3. Available from: http://www.e-ijd.org/text.asp?2011/56/1/122/77580


Sir,

We read with interest Dr Dhar's perspective on use of high-dose intravenous immunoglobulin (hd-IVIG) in dermatological conditions [1] and wish to comment on some of the important issues raised by the author. In our opinion, hd-IVIG has a rather limited role in the treatment of hypersensitive dermatoses.

The author has further suggested saving of IVIG samples prior to every infusion. This is neither necessary nor recommended as per international guidelines. [2],[3] It has been recommended and is considered a good clinical practice to save serum samples for one-off infusions and annually for those on long-term therapy so as to enable "look-back" studies in case of viral outbreaks. [2],[3] Records of batch numbers of immunoglobulin products should be maintained so that product recall can be facilitated, if required in the future. Although manufacturers of all IVIG preparations routinely employ viral inactivation techniques (solvent/detergent process that destroys lipid-coated viruses) as well as polymerase chain reaction screening tests to detect known viruses (HIV-1, HIV-2, hepatitis B surface antigen, and hepatitis C viruses), any new positive serology (post-IVIG infusion) should be properly investigated and notified to the relevant authorities.

Of the several IVIG preparations currently available in India, only one product ImmunoRel (5% preparation) from Reliance Life Sciences, has the manufacturing plant based in India, while the rest of the products are sourced from abroad. [4] So far, to the best of our knowledge, there has been no case of HIV transmission via immunoglobulin therapy, and therefore, monitoring of hepatitis B and C [yearly monitoring with hepatitis B surface antigen (HbsAg) and hepatitis C PCR for patients with antibody deficiency on long-term IVIG] is considered to be sufficient.

Even though hd-IVIG works in many dermatological conditions, clinicians must consider use of adjunctive therapy than just hd-IVIG, as concurrent immunosuppression (such as using anti-CD20 monoclonal antibody, Rituximab) has a synergistic effect with hd-IVIG [5] and can lead to long-term tolerance which is the proposed "vaccinal effect" of Rituximab. [5] Data from uncontrolled studies and case reports should be interpreted with caution, as often only favorable outcomes end up being published. Several confounding factors like differences in IVIG preparations, dosing schedules, use of concurrent immunosuppression and disease severity may affect the outcome of a given disease in an individual patient, and not just hd-IVIG on its own.

 
   References Top

1.Dhar S. Use of intravenous immunoglobulin in dermatology. Indian J Dermatol 2009;54:77-9.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.Provan D, Chapel HM, Sewell WA, O'Shaughnessy D. Prescribing intravenous immunoglobulin: summary of Department of Health Guidelines. BMJ 2008;337:990-2.  Back to cited text no. 2
    
3.Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117:S525-53.  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  
4.Singh S. Primary immunodeficiency disorders in India: The physician perspective. Pharmaceuticals Policy Law 2008;10:121-30.  Back to cited text no. 4
    
5.Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355:1772-9.  Back to cited text no. 5
[PUBMED]  [FULLTEXT]  




 

Top
Print this article  Email this article
 
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (272 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed1805    
    Printed45    
    Emailed0    
    PDF Downloaded87    
    Comments [Add]    

Recommend this journal